// App-Quantinova.ai

2299 : Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Paul G. Richardson

Principal Investigators

  • Hang Quach

  • Suzanne Trudel

  • David Routledge

  • Kevin Song

  • Hareth Nahi

  • Sofia Paul

  • Josephine Khan

  • Maria Brouch

  • Geraldine Ferron-Brady

  • Anne Yeakey

  • Chris Shelton

  • Rocio Montes de Oca

  • L. Mary Smith

  • Ellie Im

  • Christoph M Ahlers

  • Elaine M Paul

  • Beata Holkova

  • Ira Gupta

  • Brandon E. Kremer

  • Paula Rodriguez-Otero

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Univ of Melbourne/St.Vincent's Hosp Melbourne, Melbourne, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Clinical Haematology,Peter MacCallum Cancer Centre and The Royal Melbourne Hospital,Melbourne,Australie

  • Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia

  • Vancouver General Hospital, Vancouver, BC, Canada

  • Karolinska University Hospital, Stockholm, Sweden

  • GlaxoSmithKline, Upper Providence, PA

  • GlaxoSmithKline, Stevenage, United Kingdom.

  • GlaxoSmithKline, Research Triangle Park, NC

  • Experimental Medicine Unit Oncology, GlaxoSmithKline, Philadelphia, PA

  • SpringWorks Therapeutics,Stamfo

  • GlaxoSmithKline, Waltham, MA

  • Clinical Development, GlaxoSmithKline, Upper Providence, PA

  • Clínica Universidad de Navarra-Pamplona, Navarra, Spain

Locations

  • United States

  • Australia

  • Canada

  • Sweden

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • GSK2857916

  • PF-03084014

  • Dostarlimab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cohort

Phase

  • NA

Study Id's

  • NCT03525678

  • NCT04126200

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved